Details for Patent: 7,651,698

Which drugs does patent 7,651,698 protect, and when does it expire?

Patent 7,651,698 protects ORAVIG and is included in one NDA.

This patent has twenty-four patent family members in fourteen countries.

Summary for Patent: 7,651,698

Title:	Prolonged release bioadhesive therapeutic systems
Abstract:	The present invention concerns a prolonged release bioadhesive mucosal therapeutic system containing at least one active principle, with an active principle dissolution test of more than 70% over 8 hours and to a method for its preparation. This bioadhesive therapeutic system comprises quantities of natural proteins representing 50% by weight of active principle and at least 20% by weight of said tablet, between 10% and 20% of a hydrophilic polymer, and compression excipients, and comprising between 4% and 10% of an alkali metal alkylsulphate to reinforce the local availability of active principle and between 0.1% and 1% of a monohydrate sugar.
Inventor(s):	Aiache; Jean-Marc (Paris, FR), Costantini; Dominique (Paris, FR), Chaumont; Christine (Paris, FR)
Assignee:	Bioalliance Pharma (Paris, FR)
Application Number:	11/113,072
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Dosage form;

Drugs Protected by US Patent 7,651,698

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Galt Pharms	ORAVIG	miconazole	TABLET;BUCCAL	022404-001	Apr 16, 2010		RX	Yes	Yes						TREATMENT OF OROPHARYNGEAL CANDIDIASIS

Foreign Priority and PCT Information for Patent: 7,651,698

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
France	01 09811	Jul 23, 2001

International Family Members for US Patent 7,651,698

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	373464
Austria	411003
Canada	2455633
China	101524337